Both in the context of exclusively dietary interventions and after bariatric surgery or treatment with GLP(glucagon-like peptide)-1 analogs, there is not only a reduction in weight, but also a loss of muscle mass to varying degrees. A differentiated clinical examination shows that this loss does not necessarily equate to a functional deterioration.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Modern therapeutic approaches for melanoma
Innovative strategies to overcome immunotherapy resistance
- Irritable Bowel Syndrome
“Best practice” recommendations for step-by-step clarification and stage-adapted therapy
- Nutritional supplements and cognition
5-HTP: The serotonin booster for cognition in old age
- Pulmonary hypertension
PH and lung diseases
- CRC, AML and melanoma in focus
Molecular mechanisms of tumor plasticity
- Friedreich's ataxia
Interim analyses of the PROFA study show “Unmet needs”
- Polypharmacy: use of eHealth tools in Switzerland
Survey study in primary care
- Treatment of type 2 diabetes: paradigm shift continues